Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2016 by University of Washington
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Washington
ClinicalTrials.gov Identifier:
NCT01641068
First received: July 12, 2012
Last updated: November 28, 2016
Last verified: November 2016
  Purpose
The purpose of this study is to examine thinking abilities, mood, and quality of life in cancer survivors before and after an 8-week group-based memory and thinking skills workshop. Research participants will include people treated for cancer in the past. Researchers would like to know if there is a relationship between baseline performance on timed attention and memory tasks before receiving memory and thinking skills workshop designed to improve cognition, and performance on such tasks after the workshop.

Condition Intervention
Breast Carcinoma
Cancer Survivor
Cognitive Side Effects of Cancer Therapy
Malignant Female Reproductive System Neoplasm
Other: Cognitive Intervention
Other: Educational Intervention
Procedure: Functional Magnetic Resonance Imaging
Other: Memory Intervention
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: Behavioral and Neural Indices of Cognitive Rehabilitation in Women's Cancer: A Pilot Study

Resource links provided by NLM:


Further study details as provided by University of Washington:

Primary Outcome Measures:
  • Change in score on the FACT-Cog-addendum, quality of life (SF-36) questionnaire [ Time Frame: Pre-workshop to 7 weeks post-workshop ] [ Designated as safety issue: No ]
    Participants respond to questions about their quality of life. The resulting score pre-workshop is compared to the score at 7 weeks post-workshop.

  • Change in score on the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) questionnaire [ Time Frame: Pre-workshop to 7 weeks post-workshop ] [ Designated as safety issue: No ]
    Participants respond to questions about their perceived cognitive function. The resulting score pre-workshop is compared to the score at 7 weeks post-workshop.

  • Changes in neural function measured by fMRI BOLD signal [ Time Frame: Pre-workshop to 7 weeks post-workshop ] [ Designated as safety issue: No ]
    MRI functional imaging assessments while performing cognitive tasks.


Estimated Enrollment: 30
Study Start Date: September 2012
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I (memory and thinking skills workshop)
Patients participate in a memory and thinking skills workshop once weekly for 7 weeks. Patients complete cognitive tests and questionnaires at pre-baseline (Visit 1), baseline (Visit 2), and 7 weeks (Visit 3).
Other: Cognitive Intervention
Participate in memory and thinking skills workshop
Procedure: Functional Magnetic Resonance Imaging
Undergo functional neuroimaging
Other Names:
  • fMRI
  • FUNCTIONAL MRI
Other: Memory Intervention
Participate in memory and thinking skills workshop
Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment
Other: Questionnaire Administration
Ancillary studies
Active Comparator: Arm II (Education Workshop)
Patients participate in 7 weekly 1-hour group workshops focusing on increasing knowledge and education on the brain and cognition. Patients complete cognitive tests and questionnaires at pre-baseline (Visit 1), baseline (Visit 2), and 7 weeks (Visit 3). Patients are then given the option to participate in the memory and thinking skills workshop.
Other: Educational Intervention
Participate in workshops focusing on increasing knowledge and education on the brain and cognition
Other Names:
  • Education for Intervention
  • Intervention by Education
  • Intervention through Education
  • Intervention, Educational
Procedure: Functional Magnetic Resonance Imaging
Undergo functional neuroimaging
Other Names:
  • fMRI
  • FUNCTIONAL MRI
Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment
Other: Questionnaire Administration
Ancillary studies

Detailed Description:

PRIMARY OBJECTIVES:

I. To objectively assess changes in cognitive performance and quality of life (QOL) pre and post participation in a cognitive rehabilitation intervention in gynecologic and breast cancer survivors who have undergone chemotherapy.

II. To measure changes in neural function as measured by functional magnetic resonance imaging (fMRI) blood oxygenation level dependent (BOLD) signal and corresponding behavioral responses while performing cognitive tasks.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I (Skills workshop): Patients participate in a memory and thinking skills workshop once weekly for 7 weeks. Patients complete cognitive tests and questionnaires at pre-baseline (Visit 1), baseline (Visit 2), and 7 weeks (Visit 3).

ARM II (Education workshop): Patients participate in education workshop for 7 weeks 1-hour duration group focusing on the brain and cognition. Patients complete cognitive tests and questionnaires at pre-baseline (Visit 1), baseline (Visit 2), and 7 weeks (Visit 3).

  Eligibility

Ages Eligible for Study:   21 Years to 90 Years   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjective concern about declines in cognitive functioning related to a diagnosis of cancer and/or cancer related treatment
  • Prior treatment of gynecologic or breast cancer with chemotherapy
  • Completion of treatment (e.g., chemotherapy, radiation therapy, surgery, etc.) for gynecologic or breast cancer 6 months or greater in the past
  • Able to comprehend and speak English
  • For the subset of participants who will undergo magnetic resonance imaging (MRI), ability to withstand lying down in small area (MRI scanner) for 50 minutes
  • Completion of successful fMRI safety screening
  • Able to give informed consent
  • Able to undergo informed consent procedures and 3 hours of testing, plus 8 1-hour cognitive rehabilitation sessions with breaks

Exclusion Criteria:

  • Ongoing treatment for ovarian or other cancer (e.g., chemotherapy, radiation, surgery, etc.)
  • Cancer onset before the age of 21
  • Unstable medical problems (such as unstable heart disease, unstable hypertension, diabetes in poor control, respiratory disease complicated by hypoxia or hypercapnia, infectious illnesses, unstable thyroid dysfunction, currently hospitalized)
  • History of, or current symptoms of, serious psychiatric disorder requiring antipsychotic medications or hospitalization; mild depression or stable anti-depressants, and anti-seizure medications are acceptable; anti-anxiety medications may be acceptable
  • Current alcohol over-use as defined by currently consuming 4 drinks or more per day or binge drinking (6 or more drinks in one night) within the past week
  • History of or current neurological illness that significantly impacts cognition (e.g. stroke, multiple sclerosis, Parkinson's disease, Alzheimer's disease, head injury, epilepsy, etc)
  • History of brain injury that significantly impacted cognition; as indicated responses on the Ohio State University Traumatic Brain Injury Identification Method (OSU TBI-ID) greater or equal to any of the following: 30 minutes or more of loss of consciousness (LOC), two or more mild cases within two weeks of each other, or any injury with loss of consciousness before the age of 15
  • History of central nervous system (CNS) tumor
  • A score of 25 or more on the Patient Health Questionnaire (PHQ-9) on the first visit
  • A score of 26 or below on the Mini Mental Status Exam (MMSE) triggers a review by an investigational team before enrolling
  • A score above 45 on the Wender Utah Rating Scale for attention deficit disorder (ADD) (WURS)
  • For the subset of participants undergoing neuroimaging:

    • Medical history or devices which make an MRI unsafe or uncomfortable (e.g., magnetic rods or pins, metal plates or screws, pacemaker)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01641068

Locations
United States, Washington
Fred Hutch/University of Washington Cancer Consortium Recruiting
Seattle, Washington, United States, 98109
Contact: UW Memory Health Research    206-667-7930    wellness@uw.edu   
Principal Investigator: Heidi J. Gray         
Sponsors and Collaborators
University of Washington
National Cancer Institute (NCI)
Investigators
Principal Investigator: Heidi Gray Fred Hutch/University of Washington Cancer Consortium
  More Information

Responsible Party: University of Washington
ClinicalTrials.gov Identifier: NCT01641068     History of Changes
Other Study ID Numbers: 7750  NCI-2012-01035  7750  P30CA015704 
Study First Received: July 12, 2012
Last Updated: November 28, 2016
Health Authority: United States: Federal Government

Keywords provided by University of Washington:
Memory
Attention
Chemo-brain
Survivor
Treatment

Additional relevant MeSH terms:
Breast Neoplasms
Genital Neoplasms, Female
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Urogenital Neoplasms

ClinicalTrials.gov processed this record on December 05, 2016